This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability (maximum tolerated dose) after five ascending single doses of NNC 90-1170 (liraglutide).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
34
Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
Subjects receiving the dose level 5 mcg/kg s.c. will in addition receive, after a wash-out of at least 7 days, a single i.v. (into the vein) dose of 5 mcg/kg
Administered s.c. After a wash-out of at least 7 days, a single i.v. (into the vein) dose is administered
Novo Nordisk Investigational Site
Manchester, United Kingdom
AUC (area under the curve)
Cmax, maximum concentration
tmax, time to maximum concentration
t½, terminal half-life
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order